ETS transcription factors as cardiac maintenance regulators: linking RAF-ERK-PNT signaling to adult cardiac hypertrophy

Active Grant Awarded

Award ID
F31HL189275
Recipient
Awarding agency
Obligated
$38,314

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 14% complete
Place of performance
La Jolla, CA 92037, USA

Award details come from USAspending.gov.

Description

Abstract
Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous cardiac disorder characterized by ventricular wall thickening, interstitial fibrosis, and impaired cardiac output, often culminating in heart failure or sudden cardiac death. Among the genetic causes of HCM are pathogenic variants in the RAS/mapk signaling cascade, a core regulator of cellular growth. Aberrant activation of the RAF-MEK-ERK signaling cascade is a defining feature of rasopathies and drives hypertrophic cardiomyopathy (HCM) in both humans and model systems. ERK phosphorylates and activates ETS transcription factors such as PNTP2, suggesting that ETS proteins serve as key transcriptional effectors downstream of mapk signaling. However, the stage-specific roles of ETS factors in the heart, the requirement for ERK-dependent phosphorylation, and the transcriptional programs activated by ETS in vivo remain unknown. In parallel, calcineurin-dependent activation of crtc represents a second major hypertrophic signaling axis that remodels metabolic and stress-responsive gene networks, but whether ETS integrates or cooperates with can-crtc signaling to drive cardiac growth has not been investigated. This proposal uses the genetically tractable drosophila heart, an established model for structural and functional cardiac disease, to define how ERK-ETS signaling remodels the adult myocardium and whether IT converges with can-crtc pathways to produce hypertrophy. Aim 1 determines when ETS activation is required during development and adulthood and tests whether ERK-mediated phosphorylation of PNTP2 is essential for hypertrophic remodeling. Aim 2 uses single-nucleus RNA sequencing and spatial transcriptomics to identify ETS- dependent cell states and downstream transcriptional modules in cardiomyocytes and pericardial cells. Aim 3 tests whether ETS cooperates with, or functions independently of, the calcineurin-crtc transcriptional module to drive pathological growth. The studies will define the signaling logic and transcriptional networks that underlie cardiomyocyte hypertrophy, identify novel ETS-regulated effectors, and determine how metabolic and mapk pathways converge to promote pathological remodeling. This work will establish a mechanistic framework for understanding hypertrophic cardiomyopathy and uncover conserved targets for therapeutic intervention in rasopathies and metabolic heart disease.

Quick answers

Who received award F31HL189275?

F31HL189275 was awarded to Sanford Burnham Prebys Medical Discovery Institute by National Heart Lung and Blood Institute (National Institutes of Health) on September 4, 2026.

How much is award F31HL189275 worth?

$38,314 has been obligated on F31HL189275.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award